Abstract SIOP 2019: ALK SIOPEN

Genetic alterations of ALK in high-risk neuroblastoma patients. A SIOPEN study.

Angela Bellini1, Virginie Bernard1, Inge Ambros2, Peter F. Ambros2, Kateen de Preter3, Valérie Combaret4, Klaus Beiske5, Marta Jeison6, Barbara Marques7, Martina Morini8, Katia Mazzocco9, Raffaella Defferrari10, David Betts9, Tommy Martinsson10, Annick Mühlethaler-Mottet11, Rosa Noguera12, Jaime Font de Mora12, Ales Vicha13, Ruth Ladenstein14, Dominique Valteau-Couanet15, Caroline Maria Rossing16, Nick Bown17, Deborah Tweddle18, Smadar Avigad19, Eve Lapouble1, Mathieu Chicard1, Nada Leprovost1, Nathalie Clement1, Sylvain Baulande1, Gaelle Pierron1, Jimenez Irene1, Hbalshankar Jaydutt1, Olivier Delattre1, Jean Michon1, Gudrun Schleiermacher1

1 Institut Curie, Paris, France
2 Children’s Cancer Research Institute, Vienna, Austria
3 Ghent University, Ghent, Belgium
4 Centre Léon Berard, Lyon, France
5 Oslo University Hospital, Oslo, Norway
6 Schneider Children’s Medical Center of Israel, Tel Aviv University, Israel
7 Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal
8 Istituto G. Gaslini, Genoa, Italy
9 Department of Clinical Genetics, Our Lady's Children's Hospital, Dublin, Ireland
10 Clinical Genetics, Sahlgrenska Academy at the University of Gothenburg
11 University Hospital CHUV, Lausanne, Switzerland
12 Hospital Universitario y Politécnico La Fe, Valencia, Spain
13 Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
14 St Anna Children’s Hospital, Vienna, Austria
15 Gustave Roussy, Villejuif, France
16 Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
17 Northern Genetics Service, Newcastle upon Tyne, Newcastle, UK
18 Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE1 7RU, UK
19 Schneider Children’s Medical Center of Israel, Pediatric Hematology Oncology, Petah Tikva, Israel.

Background: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through genomic amplification or activating point mutations. We studied ALK genetic alterations in high-risk NB patients to determine their frequency and prognostic impact.

Methods: Diagnostic NB samples from 1039 patients enrolled in the SIOPEN-HR-NBL1 trial were studied to determine the ALK amplification status (copy number analysis; n=337), the ALK mutational profile (Sanger and/or NGS including deep sequencing, n=203) or both (n=499).

The sensitivity of ALK mutated/ALK amplified or ALK wildtype NB cell lines (((CLB-GA (R1275Q), CLB-GE (F1174V; ALK-A), SKNBE-2C (ALK wt))) to simultaneous or
consecutive combinations of ALK TKIs (crizotinib/lorlatinib) and/or chemotherapy (Etoposide and Doxorubicin) was then tested.

Results: Genomic ALK amplifications were detected in 4.4% of cases (37/836); all but 2 showed MYCN amplification. ALK mutations were detected at a clonal level (>20% mutated allele fraction, MAF) in 9.8% of cases (69/702) (F1174 n=25, R1275 n=32, both F1174 and R1275 n=1, F1245 n=6, others n=5) and at a subclonal level (MAF 0.5-20%) in 3.7% of patients (22/586) (F1174 n=11, R1275 n=6, both F1174 and R1275 or F1174 and F1245 n=3, other n=2).

A significantly poorer OS and EFS was observed in cases with clonal ALK mutations, versus all others (3-years OS 47% +/-6.4% versus 65% +/-2%, logrank, p< 0.0001) and in those with ALK amplifications, versus all others (3-years OS 31% +/-8.5% versus 66% +/- 1.9%; logrank, p<0.0001).

A Cox proportional hazards procedure (450 patients with complete clinical/biological datasets) retained stage 4 disease (as opposed to non-stage 4) and ALK amplification as factors with a higher hazard of relapse/progression (hazard 2.3 and 2.2, respectively), whereas ALK mutation, MYCN amplification and age>18 months were not retained.

The consecutive treatment of Doxorubicin followed by Lorlatinib had a synergistic effect in ALK mutated/amplified NB cell lines.

Conclusion: Genetic alterations of ALK (clonal mutations, amplifications) in high-risk NB patients are associated with poorer survival. Further preclinical data are required to determine optimal treatment modalities for integration of TKI in upfront treatment strategies of HR NB patients with ALK alterations.